Calpain-10 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Calpain-10 (CAPN10; UniProt Q9HC96), expressed in HEK293 cells. Suited for calcium-dependent protease activity assays, inhibitor profiling, and antibody validation standards.
Expression system
HEK293
Cat. #
REC-Calpain10

In stock

SKU
REC-Calpain10
$498.00

Target Overview

Calpain-10 is a calcium-regulated, non-lysosomal cysteine protease encoded by CAPN10 (UniProt Q9HC96) and belonging to the large calpain superfamily. Unlike the classical calpain heterodimers (calpain-1 and -2), Calpain-10 is an atypical family member that lacks the canonical penta-EF-hand domain found in regulatory subunits; instead, it carries three divergent calpain-type domains (domains I–III) plus a C-terminal domain III-like region across its 672-amino-acid sequence. The protein functions as a calcium-activated thiol protease that catalyzes limited, regulated proteolysis of substrates implicated in cytoskeletal remodeling and intracellular signal transduction, with published evidence for a role in insulin-stimulated glucose uptake. This recombinant form is produced in HEK293 cells, providing a mammalian expression background that supports the post-translational processing and folding relevant to enzymatic studies. It is suitable for substrate cleavage assays using fluorogenic peptide substrates or native targets such as microtubule-associated proteins, for inhibitor IC₅₀ determination in small-molecule screens, and for biophysical characterization of calcium-dependent activation kinetics. Researchers requiring a well-defined positive control for Western blot or immunohistochemistry should note that this recombinant is validated for use alongside the Triple Point Biologics matched anti-Calpain-10 polyclonal antibody (SKU: RP-Calpain10), which cross-links directly from this page. Using the recombinant as an antibody validation standard eliminates ambiguity about band identity in complex tissue lysates, a common requirement when establishing CAPN10 detection in novel sample types.

Background

Calpain-10 was the first member of the calpain superfamily to be identified as a susceptibility locus for a common complex disease — type 2 diabetes mellitus (T2DM) — through positional cloning studies of chromosome 2q37. The CAPN10 gene harbors several non-coding and intronic variants (including the frequently studied UCSNP-43, UCSNP-19, and UCSNP-63 haplotypes) that have been investigated in population genetics and pharmacogenomics research across multiple ethnic cohorts. The intronic insertion/deletion variant known as Indel-19 (UCSNP-19) has been evaluated for association with chronic metabolic diseases; Meza-Espinoza et al. (2025, BMC Res Notes) examined this variant in a Mexican population, providing negative association data that inform the broader picture of CAPN10 genetic architecture across diverse ancestries. At the molecular level, Calpain-10 catalyzes calcium-dependent limited proteolysis of substrates involved in cytoskeletal dynamics and signal transduction, and has been studied in the context of insulin signaling and glucose transporter trafficking — pathways central to metabolic syndrome research. Published pharmacogenomics work has explored whether CAPN10 variants modulate response to antidiabetic agents including metformin, making the recombinant protein a useful tool for in vitro mechanistic studies that complement genotype-association findings. Beyond metabolic research, database mining studies have placed CAPN10 within autophagy-related gene expression networks in hepatocellular carcinoma, and druggable genome-wide Mendelian randomization analyses have examined calpain-family members as candidate targets in pain and degenerative musculoskeletal conditions. These lines of evidence position Calpain-10 as a research target across metabolic, oncological, and musculoskeletal biology, though the mechanistic details of substrate selectivity, tissue-specific expression, and regulation remain areas of active investigation. For in vitro research, recombinant Calpain-10 enables direct enzymatic characterization that cannot be inferred from genetic association data alone. Substrate profiling, inhibitor selectivity comparisons against other calpain isoforms, and co-immunoprecipitation studies with candidate binding partners all require a defined, active recombinant protein. The HEK293-expressed form available here supports these applications and provides a species-matched human protein for studies in human cell or tissue models.

Applications

  • Calcium-dependent protease activity assay using fluorogenic peptide substrates (e.g., Suc-LLVY-AMC)
  • Inhibitor IC₅₀ determination and selectivity profiling against other calpain isoforms
  • Antibody validation positive control for Western blot alongside TPB anti-Calpain-10 (RP-Calpain10)
  • Substrate identification by co-incubation with candidate proteins (e.g., microtubule-associated proteins) followed by SDS-PAGE or mass spectrometry
  • Calcium-activation kinetics measurement by fluorescence-based enzyme kinetics (Km, Vmax determination)
  • Pull-down or co-immunoprecipitation assays to identify protein–protein interactions with signaling partners
  • Dot blot or ELISA capture antigen standard for quantification of endogenous Calpain-10 in cell lysates

References

  1. Sun A et al. Druggable Genome-Wide Mendelian Randomization Identifies Distinct Therapeutic Targets for Low Back Pain, Intervertebral Disk Degeneration, and Sciatica. J Pain Res. 2025. doi:10.2147/JPR.S542713. PMID: 41209747.
  2. Imangaliyeva AT et al. Pharmacogenetic Predictors of Metformin Response in Metabolic Syndrome and Type 2 Diabetes: Evidence from a Cohort Study in Kazakhstan. J Diabetes Res. 2025. doi:10.1155/jdr/1568889. PMID: 41050568.
  3. Yang Z et al. Phosphorylation enables progressive microtubule-associated protein proteolysis and functionalisation during neural development. bioRxiv. 2025. doi:10.1101/2025.09.19.677315. PMID: 41000643.
  4. Gu X et al. Exploring Autophagy-Related Gene Expression in Hepatocellular Carcinoma via TCGA, GEPIA2, and HPA Databases: Implications for Prognosis. J Hepatocell Carcinoma. 2025. doi:10.2147/JHC.S520917. PMID: 40726620.
  5. Meza-Espinoza JP et al. Lack of association of the calpain-10 Indel-19 variant with chronic diseases in a Mexican population. BMC Res Notes. 2025. doi:10.1186/s13104-025-07184-5. PMID: 40165210.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Cytoplasm; Ca²⁺-activated

Frequently Asked Questions

What is the expected molecular weight of recombinant Calpain-10 on SDS-PAGE or Western blot?

Recombinant Calpain-10 (REC-Calpain10) is a 672-amino-acid protein with a predicted molecular weight of approximately 74–76 kDa. On reducing SDS-PAGE, the major band typically migrates between 75 and 80 kDa due to post-translational modifications supported by the HEK293 expression system. Purity is >95% by SDS-PAGE. When using this as a Western blot standard alongside our matched antibody RP-Calpain10, expect a clean, dominant band in that range with minimal degradation products if handled correctly.

Is this recombinant Calpain-10 the full-length protein or a processed/truncated isoform?

REC-Calpain10 is produced as the full-length 672-amino-acid human sequence (UniProt Q9HC96), expressed in HEK293 cells to support native-like folding and post-translational processing. Unlike classical calpain-1/2, Calpain-10 does not require heterodimerization with a regulatory small subunit (CAPNS1) for activity, so the full-length monomer represents the physiologically relevant catalytic form. No artificial truncations have been introduced; the protein retains all three calpain-type domains (I–III) plus the C-terminal domain III-like region.

What substrates does Calpain-10 cleave and which fluorogenic peptide substrate works for activity assays?

Calpain-10 is a calcium-activated cysteine protease with activity toward cytoskeletal and signaling proteins implicated in insulin-stimulated glucose uptake. For in vitro fluorogenic assays, the Suc-LLVY-AMC substrate (used broadly for calpains) provides a measurable fluorescent readout; however, because Calpain-10 has divergent substrate specificity relative to calpain-1/2, the Z-LR-AMC substrate is also reported to give a stronger signal-to-noise ratio. Reactions should be run at 25–37°C in the presence of 1–5 mM CaCl₂ in assay buffer, with enzyme at 50–200 nM as a starting range.

What buffer conditions should I use for a Calpain-10 activity assay and does the storage buffer interfere?

REC-Calpain10 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. For activity assays, dilute into a working buffer of 20–50 mM Tris-HCl pH 7.4 or HEPES pH 7.4, 1–5 mM CaCl₂, 1–5 mM DTT or β-mercaptoethanol (to maintain the active-site cysteine in reduced form), and 0.1% BSA as a carrier. Glycerol carry-over at dilutions of 1:10 or greater is generally non-inhibitory. Avoid EDTA or EGTA, which chelate the calcium required for activation. Pre-incubate the enzyme with calcium for 5–10 minutes at room temperature before adding substrate.

What starting concentration of recombinant Calpain-10 should I use in a substrate cleavage or IC50 inhibitor assay?

For fluorogenic substrate cleavage assays (e.g., Suc-LLVY-AMC or Z-LR-AMC), a starting concentration of 50–200 nM REC-Calpain10 in a 50–100 µL reaction volume is recommended. Titrate down if background hydrolysis is high, or up if signal is weak after 30–60 minutes. For IC50 determinations, fix enzyme at a concentration giving 20–30% substrate conversion at the assay endpoint to maintain linear kinetics. Include a no-enzyme blank and a no-inhibitor control. Confirm protein concentration by absorbance (A₂₈₀) before each use, as freeze-thaw losses can occur even with single-use aliquots.

Can I use REC-Calpain10 as a positive control for Western blot with the RP-Calpain10 antibody?

Yes — REC-Calpain10 is the intended positive control for the matched rabbit polyclonal antibody RP-Calpain10 (/anti-calpain-10-rabbit-polyclonal-antibody). Because both products originate from the same laboratory workflow, antigen–antibody compatibility is confirmed, not inferred. Load 10–50 ng of recombinant protein per lane on a standard SDS-PAGE gel; the antibody should detect the ~75–80 kDa band cleanly at antibody dilutions of 1:500–1:2000. This pairing is particularly useful for antibody validation experiments and for confirming band identity in complex lysate backgrounds where an endogenous Calpain-10 band needs unambiguous assignment.

How much recombinant Calpain-10 should I load for a Western blot positive control lane?

Load 10–50 ng of REC-Calpain10 per lane as a starting range. At 10 ng with the RP-Calpain10 antibody at 1:1000, a strong single band at ~75–80 kDa is typically resolved without saturating the signal. If your lysate lanes are loaded at 20–40 µg total protein, 25 ng of recombinant is a practical midpoint that keeps the positive control band comparable in intensity to the endogenous signal. Running the recombinant alongside a molecular weight ladder and the antibody-validated lysate in the same blot provides a clear, publishable positive control lane.

How should I store and handle recombinant Calpain-10 to preserve activity over time?

REC-Calpain10 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and is aliquoted for single use. Store at -20°C; avoid repeated freeze-thaw cycles, which progressively reduce cysteine protease activity. Upon thawing, keep on ice and use within 4–6 hours. Do not dilute working stocks in plain water — use a carrier buffer containing 0.1% BSA and 1 mM DTT to minimize surface adsorption and oxidation of the active-site cysteine. If long-term stability data are needed for your specific assay conditions, a short activity time-course after initial thaw is advisable before committing large volumes to a screening run.

Validation imagery coming soon

Western blot validation figures for REC-Calpain10 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →